Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. PPBT.NASDAQ

Purple Biotech (PPBT NASDAQ) stock market data APIs

$0.371 -0.03(-7.5%) as of July 26, 2024
Price chart is built with Anychart

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Purple Biotech Financial Data Overview

0.3999
0.371
-
0.4
0.3616
0.3023-1.8
14 122 K
33 910 K
0
-0.14
0.383
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PPBT',
Type: 'Common Stock',
Name: 'Purple Biotech',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00B3L3T17',
ISIN: NULL,
CUSIP: NULL,
CIK: '1614744',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2015-11-20',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Purple Biotech Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -21 567 000
  • Earnings Per Share -0.79
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Purple Biotech Earnings via APIs

  • Latest Release 2024-05-21
  • EPS/Forecast -0.19

Get Purple Biotech End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Purple Biotech latest news via APIs

Purple Biotech Reports Third Quarter 2023 Financial Results

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2Dose Escalation Study Patients’Enrollment in the Phase 2 Randomized CM24 Pancreatic CancerTrial Ahead of Timelines Cash Runw...
  • EARNINGS RELEASES AND OPERATING RESULTS
  • NASDAQ:PPBT
  • PURPLE BIOTECH LTD

Purple Biotech Fortifies NT219 Patent Protection

New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company"...
  • ANTI-CANCER AGENTS
  • CANCER
  • CLINICAL STUDY
  • CLINICALSTUDY
  • HEALTH
  • INTELLECTUAL PROPERTY
  • NASDAQ:PPBT
  • ONCOLOGY
  • PATENT
  • PATENTS
  • PRESS RELEASES
  • PURPLE BIOTECH LTD
Do you have any questions?
support@eodhistoricaldata.com